NASDAQ: IMNNImunon Inc Stock
$1.95-0.07 (-3.47%)
Updated Jun 15, 2026
IMNN Price
$1.95
Fair Value Price
$3.66
Market Cap
$8.19M
52 Week Low
$1.94
52 Week High
$17.70
P/E
-0.36x
P/B
2.44x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$14.64M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.39
Operating Cash Flow
-$15M
Beta
0.83
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IMNN Overview
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IMNN's potential to beat the market
- IMNN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IMNN
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important IMNN news, forecast changes, insider trades & much more!
IMNN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMNN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMNN ($1.95) is undervalued by 46.74% relative to our estimate of its Fair Value price of $3.66 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
IMNN ($1.95) is significantly undervalued by 46.74% relative to our estimate of its Fair Value price of $3.66 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
IMNN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMNN due diligence checks available for Premium users.
Valuation
IMNN fair value
Fair Value of IMNN stock based on Discounted Cash Flow (DCF)
Price
$1.95
Fair Value
$3.66
Undervalued by
46.74%
IMNN ($1.95) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMNN ($1.95) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMNN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMNN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.36x
Industry
16.41x
Market
14.3x
IMNN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.44x
Industry
4.89x
IMNN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMNN's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.2M
Profit Margin
0%
IMNN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.0M
Liabilities
$4.7M
Debt to equity
1.39
IMNN's short-term assets ($6.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMNN's short-term assets ($6.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMNN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IMNN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.0M
Investing
$0.0
Financing
-$1.8k
IMNN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMNN vs Biotech Stocks
Imunon Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.